Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „ruxolitinib“
Suchtreffer
Begriffe & Kennungen
Ruxolitinib Viatris · 4.8 · 19 In the comparative period of the phase 3 acute GvHD study (REACH2), bleeding events were reported in 25.0%
Eintrag öffnenRuxolitinib Viatris · 4.8 · 20 with ruxolitinib, urinary tract infections and BK virus infections were reported in 9.3% (grade ≥3, 1.3%) a
Eintrag öffnenRuxolitinib Viatris · 4.8 · Acute GvHD Chronic Chronic GvHD Acute GvHD (Paediatric GvHD (Paediatric (REACH2) pool) (REACH3) pool) Frequenc
Eintrag öffnenRuxolitinib Viatris · 4.8 · Acute GvHD The most frequently reported adverse drug reactions in REACH2 (adult and adolescent patients) were
Eintrag öffnenRuxolitinib Viatris · 4.8 · Adverse drug reaction Frequency category for MF Frequency category for PV patients patients Infections and inf
Eintrag öffnenRuxolitinib Viatris · 4.8 · Adverse drug reactions from clinical studies in MF and PV (Table 6) and in acute and chronic GvHD (Table 7) ar
Eintrag öffnenRuxolitinib Viatris · 4.8 · Anaemia In phase 3 clinical studies in MF, median time to onset of first CTCAE grade 2 or higher anaemia was 1
Eintrag öffnenRuxolitinib Viatris · 4.8 · Anaemia, thrombocytopenia and neutropenia are dose-related effects.
Eintrag öffnenRuxolitinib Viatris · 4.8 · Bleeding In the phase 3 pivotal studies in MF bleeding events (including intracranial and gastrointestinal, br
Eintrag öffnenRuxolitinib Viatris · 4.8 · CTCAE grade 3 -6 -6 Common N/A5 17 CTCAE grade 4 -6 -6 N/A5 N/A5 1 Frequency is based on new or worsened labor
Eintrag öffnenRuxolitinib Viatris · 4.8 · CTCAE grade 3 -6 -6 Common N/A5 CTCAE grade 4 -6 -6 Common N/A5 Renal and urinary disorders Increased blood cr
Eintrag öffnenRuxolitinib Viatris · 4.8 · CTCAE grade 3 Common Common Common Very common CTCAE grade 4 N/A 5 N/A5 Uncommon N/A5 Musculoskeletal and conn
Eintrag öffnenRuxolitinib Viatris · 4.8 · CTCAE grade 3 Very common Very common Common Very common CTCAE grade 4 Common N/A5 Uncommon Common Increased a
Eintrag öffnenRuxolitinib Viatris · 4.8 · Chronic GvHD The most frequently reported adverse drug reactions in REACH3 (adult and adolescent patients) wer
Eintrag öffnenRuxolitinib Viatris · 4.8 · Description of selected adverse drug reactions
Eintrag öffnenRuxolitinib Viatris · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 18.1% of patients in REACH3 an
Eintrag öffnenRuxolitinib Viatris · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 19.4% of patients.
Eintrag öffnenRuxolitinib Viatris · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 29.4% of patients in REACH2 an
Eintrag öffnenRuxolitinib Viatris · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 30.0% of patients.
Eintrag öffnenRuxolitinib Viatris · 4.8 · During long-term follow-up of phase 3 studies in PV, frequently reported infections were urinary tract infecti
Eintrag öffnen